Repatha Monthly Dose Approved With On-Body Pushtronex System
Executive Summary
Amgen’s PCSK9 blocker was cleared by FDA at a 420mg dose that can be administered once monthly via a hands-free device, offering a point of differentiation versus Sanofi/Regeneron’s Praluent.
You may also be interested in...
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
In a very strong second-quarter earnings report, Amgen reports just $27m in worldwide sales for cholesterol-busting PCSK9 inhibitor Repatha, as reimbursement continues to present a big hurdle.
Keeping Track: Xiidra, New Repatha Regimen Approved; Abuse-Deterrent Opioid Gets Negative, But Timely, Response
The latest drug development news and highlights from our FDA Performance Tracker.